Tamara Saurí - Concepedia

Author

Tamara Saurí

Vall d'Hebron Hospital Universitari ORCID

Also Known As

T Sauri-Nadal, T Saurí, T. SAURI, T. Sauri, T. Sauri-Nadal, T. Saurí, Tamara Sauri, Tamara Sauri-Nadal, Tamara Saurí

Publications

517

Citations

H-Index

Concepts

All Affiliations

Vall d'Hebron Hospital Universitari Institut Català d'Oncologia Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Duke Medical Center

About

Tamara Saurí is an author at Vall d'Hebron Hospital Universitari specializing in tumor biology, cancer therapeutics, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	84
2	Pathology	2	2	36
3	Pharmacology	2	2	69
4	Health Sciences	1	1	15
5	Cell Biology	1	1	48

Tamara Saurí

Publications

304

Citations

H-Index

Page 1

	Year	Citations
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights Rodrigo Dienstmann, Élena Elez, Guillem Argilés, Molecular Oncology	2017	54
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer Gaia Griguolo, Fara Brasó‐Maristany, Blanca González‐Farré, Cancers	2020	53
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies Cristina Oliveras‐Ferraros, Alejandro Vázquez‐Martín, Sílvia Cufí, Biochemical and Biophysical Research Communications Breast OncologyOncologyMedicineCell DeathPrimary Resistance	2011	48
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC) Johanna C. Bendell, Tamara Saurí, Antonio Cubillo Gracián, The Oncologist	2019	43
Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis Alejandro Vázquez‐Martín, Tamara Saurí, Octavio J. Menendez, Cell Cycle	2012	22
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441). Pascal Hammel, Iman El‐Hariry, Teresa Macarulla, Journal of Clinical Oncology Chemoprevention StrategyCancer ManagementPathologyPharmacotherapyTumor Biology	2022	21
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study Javier Garciá Corbacho, Alberto Indacochea, Azucena E. González Navarro, Cancer Immunology Immunotherapy	2023	19
Atherosclerosis precursors in Finnish children and adolescents. XII. Smoking behaviour and its determinants in 12–18‐year‐old subjects T. Byckling, Tamara Saurí Acta Paediatrica	1985	15
Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC). Johanna C. Bendell, Tamara Saurí, Antonio Cubillo, Journal of Clinical Oncology Surgical OncologyPathologyMcrc PtsTumor BiologyTumor Angiogenesis	2017	15
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors Édouard Auclin, Perrine Vuagnat, Cristina Smolenschi, Cancers	2021	14

Page 1